<DOC>
	<DOCNO>NCT00969436</DOCNO>
	<brief_summary>The purpose study assess non-inferiority two different vaccination regimen use GSK Biological 's MMRV vaccine ( two dose 9 15 month ) Priorix™ ( 9 month ) one dose MMRV vaccine ( 15 month ) current standard care Priorix™ administer 9 month age follow concomitant administration Priorix™ Varilrix™ 15 month age measles endemic environment India .</brief_summary>
	<brief_title>Comparison GSK Measles-mumps-rubella-varicella ( MMRV ) Vaccine Versus PriorixTM</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . Male female subject include 9 10 month age time first vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol start 30 day prior administration dose study vaccine , 42 day vaccine dose exception hepatitis A vaccine oral poliovirus vaccine . Concurrently participate another clinical study , time study period , subject expose investigational nonregistered product . Previous vaccination measles , mumps , rubella varicella . History measles , mumps , rubella and/or varicella disease . Known exposure measles , mumps , rubella and/or varicella within 30 day prior start study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine include neomycin . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Axillary temperature &gt; 37.5°C ( 99.5°F ) / Rectal temperature &gt; 38°C ( 100.4°F ) . Administration immunoglobulins and/or blood product six month enter study plan administration study period . Presence susceptible highrisk person household study period .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>10 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mumps</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccines</keyword>
	<keyword>Safety</keyword>
	<keyword>Rubella</keyword>
	<keyword>Combined Vaccine</keyword>
	<keyword>Varicella Vaccine</keyword>
	<keyword>Children</keyword>
	<keyword>Measles</keyword>
	<keyword>Humans</keyword>
</DOC>